Personalized and HPV cancer vaccines in head and neck squamous cell carcinoma: from concept to clinical implementation
Translational Oncology · 2026-05 · 67 · 102715
DOI: 10.1016/j.tranon.2026.102715 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Translational Oncology, 2026-05. Verfasst von Daria Maria Filippini und 1 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Head and neck squamous cell carcinoma (HNSCC) remains a challenging malignancy, with limited survival improvements despite recent advances with immune checkpoint inhibitors (ICIs). Within this context, personalized neoantigen vaccines and HPV-targeted therapeutic vaccines are emerging as innovative strategies aimed at enhancing antitumor immunity. Personalized vaccines exploit tumor-specific mutational landscape to generate highly individualized T cell responses, demonstrating favorable safety profiles and durable immunogenicity in early-phase trials. Compounds such as TG4050, mRNA-4157, and PGV001 have shown early, hypothesis-generating signals of activity (from small early-phase studies), particularly in the adjuvant setting. HPV-targeted vaccines, including PDS0101, BNT113, and CUE-101, are being explored in HPV-positive HNSCC, mainly in combination with ICIs. While some early clinical activity has been observed, these signals should be interpreted cautiously given limited sample sizes, heterogeneous populations, and exploratory endpoints in many studies, and randomized trials such as ISA101b have failed to show survival benefits over ICIs alone. Overall, therapeutic vaccination appears safe and immunologically active, yet its efficacy is constrained by the immunosuppressive tumor microenvironment. The greatest clinical potential of therapeutic vaccination may lie in earlier disease stages, where the tumor burden is lower and immune modulation more feasible. Further clinical and translational research is needed to define the optimal integration of vaccine-based therapies into multimodal treatment paradigms for HNSCC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy.
- Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France; INSERM U1331 Research unit, Saint-Cloud, France; Paris-Saclay University, Paris, France. Electronic address: christophe.le-tourneau@gus…
Zitieren
APA
Filippini, D. M., & Le Tourneau, C. (2026). Personalized and HPV cancer vaccines in head and neck squamous cell carcinoma: from concept to clinical implementation. Translational Oncology, 67, 102715. https://doi.org/10.1016/j.tranon.2026.102715
Vancouver
Filippini DM, Le Tourneau C. Personalized and HPV cancer vaccines in head and neck squamous cell carcinoma: from concept to clinical implementation. Translational Oncology. 2026;67:102715. doi:10.1016/j.tranon.2026.102715
BibTeX
@article{Filippini2026,
author = {Filippini, Daria Maria and Le Tourneau, Christophe},
title = {Personalized and HPV cancer vaccines in head and neck squamous cell carcinoma: from concept to clinical implementation},
journal = {Translational Oncology},
year = {2026},
volume = {67},
pages = {102715},
doi = {10.1016/j.tranon.2026.102715}
}
EUVIMED